They could also show that FcγRIV-positive macrophages facilitating Treg depletion were enriched in the microenvironment of tumors in mice responding to CTLA-4 treatment, underlining once again the importance of modifying the tumor microenvironment for a successful immune checkpoint blockade therapy. The gene discussed is CTLA4; the disease is neoplasm.